Trial Information - Phase III
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
Protocol ID: MK-3475-C93/GOG-3064
Sponsor: GOG Foundation /Merck & Co., Inc.
Status: OPEN TO ENROLLMENT
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724